4.3 Article

Coordination between TGF- cellular signaling and epigenetic regulation during epithelial to mesenchymal transition

Journal

EPIGENETICS & CHROMATIN
Volume 12, Issue -, Pages -

Publisher

BMC
DOI: 10.1186/s13072-019-0256-y

Keywords

Epithelial to mesenchymal transition; Time-resolved quantitative (phospho)proteomics; Comprehensive profiling of histone modifications; Erk signaling; Histone H3 lysine 27 trimethylation; Combinatorial inhibition targeting signaling pathway and epigenetic regulator

Funding

  1. NIH [AI118891, CA196539, GM110104, GM120953]
  2. NATIONAL CANCER INSTITUTE [P01CA196539] Funding Source: NIH RePORTER

Ask authors/readers for more resources

BackgroundEpithelial to mesenchymal transition (EMT) plays a crucial role in cancer propagation. It can be orchestrated by the activation of multiple signaling pathways, which have been found to be highly coordinated with many epigenetic regulators. Although the mechanism of EMT has been studied over decades, cross talk between signaling and epigenetic regulation is not fully understood.ResultsHere, we present a time-resolved multi-omics strategy, which featured the identification of the correlation between protein changes (proteome), signaling pathways (phosphoproteome) and chromatin modulation (histone modifications) dynamics during TGF--induced EMT. Our data revealed that Erk signaling was activated in 5-min stimulation and structural proteins involved in cytoskeleton rearrangement were regulated after 1-day treatment, constituting a detailed map of systematic changes. The comprehensive profiling of histone post-translational modifications identified H3K27me3 as the most significantly up-regulated mark. We thus speculated and confirmed that a combined inhibition of Erk signaling and Ezh2 (H3K27me3 methyltransferase) was more effective in blocking EMT progress than individual inhibitions.ConclusionsIn summary, our data provided a more detailed map of cross talk between signaling pathway and chromatin regulation comparing to previous EMT studies. Our findings point to a promising therapeutic strategy for EMT-related diseases by combining Erk inhibitor (singling pathway) and Ezh2 inhibitor (epigenetic regulation).

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available